Showing results (161-170 of 425) with videos related to
Sort By:
Pageof 43
JAMA Network Open|August 24, 2022
Assessment of Oncologists' Perspectives on Omission of Sentinel Lymph Node Biopsy in Women 70 Years and Older With Early-Stage Hormone Receptor-Positive Breast CancerChristina A Minami, Ava F Bryan, Rachel A Freedman, et al.Cancer|March 26, 2010
A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patientsIsabelle Bedrosian, Gildy V Babiera, Elizabeth A Mittendorf, et al.Cancer|April 6, 2006
Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trialElizabeth A Mittendorf, Catherine E Storrer, Rebecca J Foley, et al.Annals of Surgical Oncology|May 6, 2021
Comparison of Breast Cancer Staging Systems After Neoadjuvant ChemotherapyOlga Kantor, Alison Laws, Ricardo G Pastorello, et al.Annals of Surgical Oncology|January 10, 2020
Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer StagingOlga Kantor, Jiangong Niu, Hui Zhao, et al.Breast Cancer Research and Treatment|August 15, 2015
Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapyMisbat Chaudry, Xiudong Lei, Ana M Gonzalez-Angulo, et al.Annals of Surgical Oncology|July 31, 2021
Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging SystemOlga Kantor, Monica L Wang, Kimberly Bertrand, et al.NPJ Breast Cancer|February 19, 2022
Immunotherapy for early triple negative breast cancer: research agenda for the next decadePaolo Tarantino, Chiara Corti, Peter Schmid, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2019
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical TrialElizabeth A Mittendorf, Biao Lu, Michelle Melisko, et al.Journal for Immunotherapy of Cancer|August 1, 2019
Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancerChristina A Hartl, Adrian Bertschi, Regina Bou Puerto, et al.Pageof 43